Los Angeles, California — October 30, 2025 — Leads & Copy — eXoZymes Inc. (NASDAQ:EXOZ) CEO Michael Heltzen will participate in the ‘AI’s Billion-dollar Bet on Life Sciences’ panel at Beryl Elites’ 7th Annual Investment Conference in New York City on November 4, 2025.
eXoZymes has developed a biomanufacturing platform for producing natural products, using AI to optimize cell-free enzymes. Heltzen notes that this represents the third generation of enzyme engineering, which slashes evolution time, opening up a large new space of natural product molecules.
Wade Schulz from Yale will moderate the panel, with speakers including Joy Wang from Dendreon, Sanjiv Koshal from Gilead Sciences, Sandy Balkin from Royalty Pharma, and Frank Li from Stately Bio.
On Tuesday, November 4, from 10:50 to 11:40 AM EST, eXoZymes CEO, Michael Heltzen, will be on the AI’s Billion-dollar Bet on Life Sciences: From Drug Discovery to Patient Impact panel at the Beryl Elites Investment Conference – a curated Alternative Investments & Innovation Thought Leadership Conference.
Founded in 2019, the company has developed a biomanufacturing platform that – as a historic first – offers the tools and insights to design, engineer, control and optimize nature’s own natural processes to produce chemical compounds, enabling the company’s partners to upgrade traditional petro-chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced “exozymes” as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
Source: eXoZymes
